30 closest matches · ranked by relevance
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Chronic Kidney Disease
Primary: Calcium Balance — 61; 508 mg/d calcium
Control
Primary: Urinary Phosphorus Excretion — 11 percentage of fractional excretion
Hyperparathyroidism · Chronic Kidney Disease
Primary: Fractional Change in [PTH] in CKD After a 4-week Course of Sevelamer Carbonate — -11.7; 16.4 percentage of baseline [PTH]
Calcium Phosphate Kidney Stones
Primary: Urinary Calcium Phosphate Saturation — 2.38; 1.97; 2.19 no units
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Osteoporosis
Primary: Change in Parathyroid Hormone (PTH) — 8.5; 20.0 pg/mL
Post-Surgical Hypoparathyroidism
Primary: Percent Change in Fractional Excretion of Calcium (FECa) — -39 percentage of change
Autosomal Dominant Hypocalcemia (ADH)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 1 participants
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
Chronic Kidney Disease
Primary: Serum Phosphorus — 3.9; 4.2 mg/dL
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Hemodialysis · Hyperphosphatemia
Primary: Incidence of Adverse Events — 28 Participants
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36
Primary Hyperparathyroidism · Vitamin D Deficiency
Primary: Serum Parathyroid Hormone (PTH) Level
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
Chronic Allograft Nephropathy · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) — 3.5; 78.9 percentage…
Albuminuria
Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05
Chronic Kidney Disease
Primary: Serum Phosphorus Levels — 4.6; 4.6 mg/dL
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
Chronic Kidney Disease, Stage 5 · Secondary Hyperparathyroidism
Primary: Calcium Absorption Fractions Analyzed by Analysis of Variance (ANOVA) — 0.103; 0.108 Fractions — p=0.573
Calcium Deficiency · Vitamin D Deficiency
Primary: Amount of Calcium Excreted in Urine From 0 Hours up to 6 Hours Post Dose (Ca2+ Ae0-6h) — 1.07; 0.63 mmol
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Hyperphosphatemia · End-Stage Renal Disease
Primary: Change in Serum Phosphorus From Baseline to End of Treatment — -0.10; -1.86; -2.13 mg/dL — p=<0.0001
Chronic Kidney Disease
Primary: Change From Baseline in Serum-phosphate Levels at the End of Treatment. — -0.042; -0.348; -0.404; -0.644 mmol/L